Developing a Polygenic Risk Score for Weight Gain in People Treated for Psychosis—Application in a Real‐World Setting

Documenti analoghi

• National Prescribing Trends and Cost Analysis of Antidepressants, Anxiolytics, and Hypnotics in England, 2010–2023
  di: Mike Stedman, et al.
  Pubblicazione: (2025)
• Weight‐loss drugs appear beneficial for patients with substance use disorders
  Pubblicazione: (2024)
• Antipsychotic‐Treated Schizophrenia Patients Develop Inflammatory and Oxidative Responses Independently From Obesity: However, Metabolic Disturbances Arise From Schizophrenia‐Related Obesity
  di: Emre Sarandol, et al.
  Pubblicazione: (2024)
• Real‐world usage of paliperidone palmitate injection
  di: Y. W. Francis Lam
  Pubblicazione: (2025)
• Anxiolytic Medication Use in Low‐ Middle‐ and High‐Income Countries: A World Mental Health Surveys Report
  di: Dan J. Stein, et al.
  Pubblicazione: (2025)